LivaNova raises 2026 revenue and EPS guidance after 14.3% first-quarter sales growth
LivaNova reported first-quarter 2026 revenue of $362.3 million, up 14.3% from a year earlier, and raised its full-year 2026 revenue and adjusted diluted earnings per share guidance. GAAP diluted EPS was $0.40, compared with a loss of $6.01 a year earlier that included a $360.4 million SNIA environmental liability expense, and adjusted diluted EPS rose to $0.98 from $0.88.
Key points
- Q1 revenue of $362.3 million rose 14.3% reported and 11.1% in constant currency; Cardiopulmonary revenue rose 18.3%.
- GAAP diluted EPS was $0.40 versus a loss of $6.01 in Q1 2025; adjusted diluted EPS was $0.98 versus $0.88.
- 2026 adjusted diluted EPS guidance raised to $4.20 to $4.30 from $4.15 to $4.25; revenue growth guidance raised to 7.0% to 8.0% from 6.0% to 7.0% in constant currency.
- FDA granted premarket approval for the aura6000 System for moderate to severe obstructive sleep apnea.
The filing
Written by AI on Nov 8, 2026, 1:00 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.